Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Rother, Nils ^a   Van der Vlag, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Autoimmunity; Systemic lupus erythematosus; T cells; TCR signaling; Th17 cells; Tregs

Indexed keywords

CD28 ANTIGEN; CD3 ANTIBODY; CD4 ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN KINASE C; PROTEIN KINASE LCK; PROTEIN KINASE SYK; PROTEIN TYROSINE PHOSPHATASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM SIGNALING; CONTROLLED STUDY; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; PATHOGENESIS; PHOSPHORYLATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH17 CELL; TISSUE INJURY;

EID: 84949677808     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00610     Document Type: Review

References (104)

1. Mohan C, Adams S, Stanik V, Datta SK. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med (1993) 177:1367-81. doi:10.1084/jem.177.5.1367.
2. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med (2003) 349:1526-33. doi:10.1056/NEJMoa021933.
3. Tsokos GC. Systemic lupus erythematosus. N Engl J Med (2011) 365:2110-21. doi:10.1056/NEJMra1100359.
4. Weckerle CE, Niewold TB. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol (2011) 40:42-9. doi:10.1007/s12016-009-8192-4.
5. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus (2008) 17:371-5. doi:10.1177/0961203308089990.
6. Pieterse E, van der Vlag J. Breaking immunological tolerance in systemic lupus erythematosus. Front Immunol (2014) 5:164. doi:10.3389/fimmu.2014.00164.
7. Dieker J, Hilbrands L, Thielen A, Dijkman H, Berden JH, van der Vlag J. Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice. Arthritis Res Ther (2015) 17:103. doi:10.1186/s13075-015-0617-2.
8. Dieker J, Tel J, Pieterse E, Thielen A, Rother N, Bakker M, et al. Circulating apoptotic microparticles in SLE patients drive the activation of DC subsets and prime neutrophils for NETosis. Arthritis Rheumatol (2015). doi:10.1002/art.39417.
9. Dieker JW, Fransen JH, van Bavel CC, Briand JP, Jacobs CW, Muller S, et al. Apoptosis-induced acetylation of histones is pathogenic in systemic lupus erythematosus. Arthritis Rheum (2007) 56:1921-33. doi:10.1002/art.22646.
10. Price JV, Tangsombatvisit S, Xu G, Yu J, Levy D, Baechler EC, et al. On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions. Nat Med (2012) 18:1434-40. doi:10.1038/nm.2913.
11. van Bavel CC, Dieker JW, Kroeze Y, Tamboer WP, Voll R, Muller S, et al. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann Rheum Dis (2011) 70:201-7. doi:10.1136/ard.2010.129320.
12. van Bavel CC, Dieker JW, Tamboer WP, van der Vlag J, Berden JH. Lupus-derived monoclonal autoantibodies against apoptotic chromatin recognize acetylated conformational epitopes. Mol Immunol (2010) 48:248-56. doi:10.1016/j.molimm.2010.08.003.
13. Alunno A, Bartoloni E, Bistoni O, Nocentini G, Ronchetti S, Caterbi S, et al. Balance between regulatory T and Th17 cells in systemic lupus erythematosus: the old and the new. Clin Dev Immunol (2012) 2012:823085. doi:10.1155/2012/823085.
14. Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 6:317-25. doi:10.1038/nrrheum.2010.60.
15. Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol (2008) 20:519-25. doi:10.1097/BOR.0b013e328304b6b5.
16. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature (1998) 395:82-6. doi:10.1038/25764.
17. Campi G, Varma R, Dustin ML. Actin and agonist MHC-peptide complex-dependent T cell receptor microclusters as scaffolds for signaling. J Exp Med (2005) 202:1031-6. doi:10.1084/jem.20051182.
18. Yokosuka T, Sakata-Sogawa K, Kobayashi W, Hiroshima M, Hashimoto-Tane A, Tokunaga M, et al. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat Immunol (2005) 6:1253-62. doi:10.1038/ni1272.
19. Kane LP, Lin J, Weiss A. Signal transduction by the TCR for antigen. Curr Opin Immunol (2000) 12:242-9. doi:10.1016/S0952-7915(00)00083-2.
20. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell (1992) 71:649-62. doi:10.1016/0092-8674(92)90598-7.
21. Rossy J, Williamson DJ, Benzing C, Gaus K. The integration of signaling and the spatial organization of the T cell synapse. Front Immunol (2012) 3:352. doi:10.3389/fimmu.2012.00352.
22. Samelson LE. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol (2002) 20:371-94. doi:10.1146/annurev.immunol.20.092601.111357.
23. Rincon M, Flavell RA, Davis RJ. Signal transduction by MAP kinases in T lymphocytes. Oncogene (2001) 20:2490-7. doi:10.1038/sj.onc.1204382.
24. Oh-hora M, Rao A. Calcium signaling in lymphocytes. Curr Opin Immunol (2008) 20:250-8. doi:10.1016/j.coi.2008.04.004.
25. Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol (2003) 3:939-51. doi:10.1038/nri1248.
26. Grammatikos AP, Ghosh D, Devlin A, Kyttaris VC, Tsokos GC. Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling. PLoS One (2013) 8:e74550. doi:10.1371/journal.pone.0074550.
27. Kyttaris VC, Zhang Z, Kampagianni O, Tsokos GC. Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum (2011) 63:2058-66. doi:10.1002/art.30353.
28. Takeuchi T, Suzuki K, Kondo T, Yoshimoto K, Tsuzaka K. CD3 zeta defects in systemic lupus erythematosus. Ann Rheum Dis (2012) 71(Suppl 2):i78-81. doi:10.1136/annrheumdis-2011-200641.
29. Pang M, Setoyama Y, Tsuzaka K, Yoshimoto K, Amano K, Abe T, et al. Defective expression and tyrosine phosphorylation of the T cell receptor zeta chain in peripheral blood T cells from systemic lupus erythematosus patients. Clin Exp Immunol (2002) 129:160-8. doi:10.1046/j.1365-2249.2002.01833.x.
30. Chowdhury B, Tsokos CG, Krishnan S, Robertson J, Fisher CU, Warke RG, et al. Decreased stability and translation of T cell receptor zeta mRNA with an alternatively spliced 3'-untranslated region contribute to zeta chain down-regulation in patients with systemic lupus erythematosus. J Biol Chem (2005) 280:18959-66. doi:10.1074/jbc. M501048200.
31. Gorman CL, Russell AI, Zhang Z, Cunninghame Graham D, Cope AP, Vyse TJ. Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematosus patients and healthy controls. J Immunol (2008) 180:1060-70. doi:10.4049/jimmunol.180.2.1060.
32. Tsuzaka K, Fukuhara I, Setoyama Y, Yoshimoto K, Suzuki K, Abe T, et al. TCR zeta mRNA with an alternatively spliced 3'-untranslated region detected in systemic lupus erythematosus patients leads to the down-regulation of TCR zeta and TCR/CD3 complex. J Immunol (2003) 171:2496-503. doi:10.4049/jimmunol.171.5.2496.
33. Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, et al. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol (2008) 181:8145-52. doi:10.4049/jimmunol.181.11.8145.
34. Tanaka S, Maeda S, Hashimoto M, Fujimori C, Ito Y, Teradaira S, et al. Graded attenuation of TCR signaling elicits distinct autoimmune diseases by altering thymic T cell selection and regulatory T cell function. J Immunol (2010) 185:2295-305. doi:10.4049/jimmunol.1000848.
35. Ghosh D, Kis-Toth K, Juang YT, Tsokos GC. CREMalpha suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells. Arthritis Rheum (2012) 64:799-807. doi:10.1002/art.33375.
36. Kyttaris VC, Wang Y, Juang YT, Weinstein A, Tsokos GC. Increased levels of NF-ATc2 differentially regulate CD154 and IL-2 genes in T cells from patients with systemic lupus erythematosus. J Immunol (2007) 178:1960-6. doi:10.4049/jimmunol.178.3.1960.
37. Juang YT, Wang Y, Solomou EE, Li Y, Mawrin C, Tenbrock K, et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest (2005) 115:996-1005. doi:10.1172/JCI22854.
38. Abdoel N, Brun S, Bracho C, Rodriguez MA, Blasini AM. Linker for activation of T cells is displaced from lipid rafts and decreases in lupus T cells after activation via the TCR/CD3 pathway. Clin Immunol (2012) 142:243-51. doi:10.1016/j.clim.2011.12.010.
39. Cedeno S, Cifarelli DF, Blasini AM, Paris M, Placeres F, Alonso G, et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling of Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol (2003) 106:41-9. doi:10.1016/S1521-6616(02)00052-9.
40. Yi Y, McNerney M, Datta SK. Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells. J Immunol (2000) 165:6627-34. doi:10.4049/jimmunol.165.11.6627.
41. Diaz-Gallo LM, Sanchez E, Ortego-Centeno N, Sabio JM, Garcia-Hernandez FJ, de Ramon E, et al. Evidence of new risk genetic factor to systemic lupus erythematosus: the UBASH3A gene. PLoS One (2013) 8:e60646. doi:10.1371/journal.pone.0060646.
42. Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest (2005) 115:3193-204. doi:10.1172/JCI24895.
43. Tan W, Sunahori K, Zhao J, Deng Y, Kaufman KM, Kelly JA, et al. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum (2011) 63:2755-63. doi:10.1002/art.30452.
44. Graham RR, Cotsapas C, Davies L, Hackett R, Lessard CJ, Leon JM, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet (2008) 40:1059-61. doi:10.1038/ng.200.
45. Morel L, Blenman KR, Croker BP, Wakeland EK. The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc Natl Acad Sci U S A (2001) 98:1787-92. doi:10.1073/pnas.98.4.1787.
46. Kyttaris VC, Tsokos GC. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr Opin Rheumatol (2011) 23:449-53. doi:10.1097/BOR.0b013e328349a242.
47. Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur J Immunol (2010) 40:569-78. doi:10.1002/eji.200939781.
48. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. Science (1998) 282:2263-6. doi:10.1126/science.282.5397.2263.
49. Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. Arthritis Rheum (2010) 62:2086-92. doi:10.1002/art.27452.
50. Ghosh D, Tsokos GC, Kyttaris VC. c-Jun and Ets2 proteins regulate expression of spleen tyrosine kinase in T cells. J Biol Chem (2012) 287:11833-41. doi:10.1074/jbc. M111.333997.
51. Sunahori K, Juang YT, Kyttaris VC, Tsokos GC. Promoter hypomethylation results in increased expression of protein phosphatase 2A in T cells from patients with systemic lupus erythematosus. J Immunol (2011) 186:4508-17. doi:10.4049/jimmunol.1000340.
52. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 430:694-9. doi:10.1038/nature02794.
53. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531-64. doi:10.1146/annurev.immunol.25.022106.141623.
54. Bonelli M, Savitskaya A, von Dalwigk K, Steiner CW, Aletaha D, Smolen JS, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol (2008) 20:861-8. doi:10.1093/intimm/dxn044.
55. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol (2005) 175:8392-400. doi:10.4049/jimmunol.175.12.8392.
56. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 201:233-40. doi:10.1084/jem.20041257.
57. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 24:179-89. doi:10.1016/j.immuni.2006.01.001.
58. Crispin JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 181:8761-6. doi:10.4049/jimmunol.181.12.8761.
59. Su D, Shen M, Li X, Sun L. Roles of gammadelta T cells in the pathogenesis of autoimmune diseases. Clin Dev Immunol (2013) 2013:985753. doi:10.1155/2013/985753.
60. Peng G, Wang HY, Peng W, Kiniwa Y, Seo KH, Wang RF. Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity (2007) 27:334-48. doi:10.1016/j.immuni.2007.05.020.
61. Li X, Kang N, Zhang X, Dong X, Wei W, Cui L, et al. Generation of human regulatory gammadelta T cells by TCRgammadelta stimulation in the presence of TGF-beta and their involvement in the pathogenesis of systemic lupus erythematosus. J Immunol (2011) 186:6693-700. doi:10.4049/jimmunol.1002776.
62. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol (2008) 9:166-75. doi:10.1038/ni1552.
63. Wong CK, Ho CY, Li EK, Lam CW. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus (2000) 9:589-93. doi:10.1191/096120300678828703.
64. Moisan J, Grenningloh R, Bettelli E, Oukka M, Ho IC. Ets-1 is a negative regulator of Th17 differentiation. J Exp Med (2007) 204:2825-35. doi:10.1084/jem.20070994.
65. Wong M, La Cava A, Singh RP, Hahn BH. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease. J Immunol (2010) 185:6563-71. doi:10.4049/jimmunol.0903401.
66. Chatterjee M, Rauen T, Kis-Toth K, Kyttaris VC, Hedrich CM, Terhorst C, et al. Increased expression of SLAM receptors SLAMF3 and SLAMF6 in systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. J Immunol (2012) 188:1206-12. doi:10.4049/jimmunol.1102773.
67. Chatterjee M, Hedrich CM, Rauen T, Ioannidis C, Terhorst C, Tsokos GC. CD3-T cell receptor co-stimulation through SLAMF3 and SLAMF6 receptors enhances RORgammat recruitment to the IL17A promoter in human T lymphocytes. J Biol Chem (2012) 287:38168-77. doi:10.1074/jbc. M112.415067.
68. Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC. Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity (2007) 40:1-8. doi:10.1080/08916930601095148.
69. Edwards LJ, Mizui M, Kyttaris V. Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol (2015) 158:221-30. doi:10.1016/j.clim.2015.04.004.
70. Alvarado-Sanchez B, Hernandez-Castro B, Portales-Perez D, Baranda L, Layseca-Espinosa E, Abud-Mendoza C, et al. Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2006) 27:110-8. doi:10.1016/j.jaut.2006.06.005.
71. Vargas-Rojas MI, Crispin JC, Richaud-Patin Y, Alcocer-Varela J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus (2008) 17:289-94. doi:10.1177/0961203307088307.
72. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol (2007) 178:2579-88. doi:10.4049/jimmunol.178.4.2579.
73. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 301:5-8. doi:10.1056/NEJM197907053010102.
74. Ytterberg SR, Schnitzer TJ. Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 25:401-6. doi:10.1002/art.1780250407.
75. Ronnblom L. Potential role of IFNalpha in adult lupus. Arthritis Res Ther (2010) 12:14. doi:10.1186/ar2884.
76. Ambrosi A, Espinosa A, Wahren-Herlenius M. IL-17: a new actor in IFN-driven systemic autoimmune diseases. Eur J Immunol (2012) 42:2274-84. doi:10.1002/eji.201242653.
77. Yasuda K, Richez C, Maciaszek JW, Agrawal N, Akira S, Marshak-Rothstein A, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol (2007) 178:6876-85. doi:10.4049/jimmunol.178.11.6876.
78. Yan B, Ye S, Chen G, Kuang M, Shen N, Chen S. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum (2008) 58:801-12. doi:10.1002/art.23268.
79. Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep (2007) 8:1142-8. doi:10.1038/sj.embor.7401099.
80. Malek TR. The biology of interleukin-2. Annu Rev Immunol (2008) 26:453-79. doi:10.1146/annurev.immunol.26.021607.090357.
81. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol (1995) 25:3053-9. doi:10.1002/eji.1830251111.
82. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science (1995) 268:1472-6. doi:10.1126/science.7770771.
83. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol (2005) 6:1142-51. doi:10.1038/ni1263.
84. Liu Z, Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med (2012) 18:871-82. doi:10.1038/nm.2752.
85. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol (2008) 38:3274-81. doi:10.1002/eji.200838950.
86. Xu L, Kitani A, Fuss I, Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol (2007) 178:6725-9. doi:10.4049/jimmunol.178.11.6725.
87. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity (2008) 29:44-56. doi:10.1016/j.immuni.2008.05.007.
88. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 112:2340-52. doi:10.1182/blood-2008-01-133967.
89. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood (2009) 113:4240-9. doi:10.1182/blood-2008-10-183251.
90. Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine (2015) 72:146-53. doi:10.1016/j.cyto.2014.12.027.
91. Yang J, Chu Y, Yang X, Gao D, Zhu L, Wan L, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum (2009) 60:1472-83. doi:10.1002/art.24499.
92. Kleinewietfeld M, Manzel A, Titze J, Kvakan H, Yosef N, Linker RA, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature (2013) 496:518-22. doi:10.1038/nature11868.
93. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic TH17 cells by inducible salt-sensing kinase SGK1. Nature (2013) 496:513-7. doi:10.1038/nature11984.
94. Mathis KW, Venegas-Pont M, Masterson CW, Wasson KL, Ryan MJ. Blood pressure in a hypertensive mouse model of SLE is not salt-sensitive. Am J Physiol Regul Integr Comp Physiol (2011) 301:R1281-5. doi:10.1152/ajpregu.00386.2011.
95. Becker AM, Dao KH, Han BK, Kornu R, Lakhanpal S, Mobley AB, et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One (2013) 8:e67003. doi:10.1371/journal.pone.0067003.
96. Zou YF, Xu JH, Tao JH, Xu SQ, Liu S, Chen SY, et al. Impact of environmental factors on efficacy of glucocorticoids in Chinese population with systemic lupus erythematosus. Inflammation (2013) 36:1424-30. doi:10.1007/s10753-013-9682-3.
97. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum (2008) 58:3309-18. doi:10.1002/art.23992.
98. Ichinose K, Juang YT, Crispin JC, Kis-Toth K, Tsokos GC. Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. Arthritis Rheum (2011) 63:523-9. doi:10.1002/art.30085.
99. Crispin JC, Keenan BT, Finnell MD, Bermas BL, Schur P, Massarotti E, et al. Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis Rheum (2010) 62:1431-7. doi:10.1002/art.27385.
100. Biswas PS, Gupta S, Chang E, Song L, Stirzaker RA, Liao JK, et al. Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice. J Clin Invest (2010) 120:3280-95. doi:10.1172/JCI42856.
101. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol (2004) 110:55-62. doi:10.1016/j.clim.2003.09.013.
102. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood (2008) 112:2101-10. doi:10.1182/blood-2007-12-126987.
103. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 62:542-52. doi:10.1002/art.27221.
104. Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature (2011) 472:491-4. doi:10.1038/nature10075.